GLP-1 receptor agonists have changed the treatment of type 2 diabetes and obesity in recent years.
Millions of people now use medicines such as semaglutide and tirzepatide because they can lower blood sugar and support significant weight loss. As their use grows, researchers are paying closer attention to their long-term safety.
A new investigation published in The BMJ has found that these medicines may slightly increase the risk of hair loss compared with other diabetes drugs. The study does not suggest that everyone taking a GLP-1 medicine will lose hair. Instead, it shows that the risk appears to be somewhat higher than with other commonly prescribed treatments.
To explore this question, researchers examined electronic medical records from the University of Pennsylvania Health System. They followed thousands of adults with type 2 diabetes who began treatment between 2019 and 2024 and compared GLP-1 medicines with SGLT-2 inhibitors and DPP-4 inhibitors.
The analysis included more than 50,000 patients across the comparison groups. Researchers used statistical methods to account for differences in age, body weight, existing illnesses, ethnicity, sex, and other medicines that could influence the results.
The study found that people taking GLP-1 receptor agonists experienced hair loss more often than people taking the comparison medicines. However, the absolute number of cases remained low, meaning most patients did not develop this side effect.
Most of the additional cases involved nonscarring alopecia, a form of hair shedding in which the hair follicles remain healthy. Because the follicles are not destroyed, new hair can often grow back once the trigger is removed or the body recovers.
Scientists think one explanation may be the rapid weight loss caused by these medicines. Fast weight loss is already known to trigger temporary hair shedding in some people. Nutrient shortages, including lower iron or zinc levels, and hormonal changes may also contribute.
The researchers noted several limitations. They did not have enough clinical detail to measure exactly how serious the hair loss was or whether it completely reversed after treatment ended. As with any observational study, unknown factors may also have influenced the findings.
Despite these limitations, the study is one of the largest to examine this question and used high-quality real-world patient data. The results remained similar across several additional analyses, increasing confidence that the association is real.
The findings do not outweigh the well-established benefits of GLP-1 medicines for many patients with diabetes or obesity.
Instead, they provide useful information that can help doctors and patients make informed treatment decisions together. Anyone concerned about hair loss should discuss the issue with a healthcare professional before making changes to their medication.
If you care about diabetes, please read studies about Vitamin D and type 2 diabetes, and to people with diabetes, some fruits are better than others.
For more health information, please see recent studies that low calorie diets may help reverse diabetes, and 5 vitamins that may prevent complication in diabetes.
Source: University of Pennsylvania Health System.
